← All trials
NCT05738447
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 15, 2023
- Primary completion
- Jan 1, 2024
- Completion date
- Jan 1, 2025
- First posted
- Feb 22, 2023
- Last posted
- Feb 22, 2023
- Enrollment
- 9
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Sichuan UniversityLead sponsor
- Sichuan UniversityOverall official - principal investigator
- Sichuan UniversityReponsible party - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.